Instantánea de Adela
2 oficinasUbicaciones
Adela’s mission is to deliver innovative and accessible blood tests that harness biology to transform cancer care and improve well-being.
Adela’s mission is to deliver innovative and accessible blood tests that harness biology to transform cancer care and improve well-being. The company is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela’s blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Adela’s first product was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in Annals of Oncology.